The shadow of "poison capsule" has not been dispelled, and the correction of drug industry's reexplosion of quality problems

Recently, the famous "poison capsule" event protagonist corrects the pharmaceutical industry and is exposed to product quality problems This time, Anhui Drug Administration found that the microbial limit test of Yanyan tablet of Changchun hi tech Pharmaceutical Co., Ltd under its control was unqualified After the highly publicized "poison capsule" incident, the revision of the pharmaceutical industry should have made great efforts in internal control and product quality However, in the next few years, the medicinal materials were mildewed, false inspection reports were made up, health products failed to pass the production approval, and the recent problems of microorganism exceeding the standard, all showed that the shadow of "poison capsule" remained In the case of weak core competitiveness and near stagnation of net profit growth, this quality problem may add difficulty to its listing Revised pharmaceutical industry's unremitting listing obsession in the past 16 years According to the enterprise investigation information, revised group was founded by xiulaigui, chairman of the board of directors in May 1995 It is a large modern private pharmaceutical enterprise integrating the scientific research, production and marketing, drug chain operation and standard cultivation of traditional Chinese Medicine of traditional Chinese medicine By the end of June 2018, the group had 142 subsidiaries with more than 100000 employees and stock assets of RMB 17 billion There are 24 dosage forms, more than 2000 varieties of medicine and health products, including 109 exclusive varieties The revised pharmaceutical industry has 10 years of internal power to strive to achieve sales revenue of 100 billion yuan, and reach the grand goal of trillion yuan by 2030 Listing and fundraising can undoubtedly provide an important help to revise the trillion revenue target of the pharmaceutical industry It is reported that the revised pharmaceutical industry began to seek listing in 2003 In October 2015, the amended pharmaceutical industry appointed UBS and Bank of China International as arrangers to assist in arranging the listing of the company on the Hong Kong stock exchange, but it failed In August 2016, the person in charge of the amended pharmaceutical industry disclosed in an interview with the media that the company is still planning to go public On July 11 of this year, Kyrgyz holdings announced that it plans to purchase 100% of the amended pharmaceutical shares through issuing shares and other means This is more obvious is to amend the drug industry's shell listing behavior But not long after that, Kyrgyz holdings received a letter of concern from the CSRC The next day, Kyrgyz holdings announced the suspension of restructuring This is the closest to a successful IPO for the pharmaceutical industry It is difficult to go public or because of many "stains" to modify the scale of pharmaceutical enterprises, so it is clear that A-share IPO can be chosen Why first choose Hong Kong stock to go public and then choose a much higher cost "shell listing"? Everything has to start with the "poison capsule" event in 2012 On April 15, 2012, the column of weekly quality report of CCTV exposed that 13 batches of drug capsules of 9 pharmaceutical companies exceeded the standard of heavy metal chromium in the title of "secrets in capsules" Revisionpharma is the most well-known of the exposed pharmaceutical companies, and it has been exposed that the chromium in its capsules exceeds the standard by up to 90 times Over the next few years, the correction industry has been repeatedly exposed to product quality problems In 2014, the modified pharmaceutical raw material stock used for the production of Feining granules was mildewed and deteriorated; there was a false inspection report, and the GMP certificate was recovered according to law In 2017, Keteling capsule produced by Sichuan Pharmaceutical Co., Ltd of the correction pharmaceutical industry was unqualified in the spot check In May 2019, the "amendment B group vitamin tablet" of health products under the amendment pharmaceutical industry failed to pass the approval of health food production In October, the microbial limit test of Yanyan tablet of Changchun hi tech Pharmaceutical Co., Ltd., a subsidiary of the pharmaceutical industry, was unqualified As a pharmaceutical enterprise, the capital market is very concerned about the quality of its products The quality problems of poison capsules and their follow-up products have become a "stain" that can not be ignored In addition, the amended pharmaceutical industry has been involved in various disputes frequently, which shows that its internal control is facing a test This is also the "stain" that the capital market attaches great importance to According to the data of enterprise investigation, there were 119 amendments to the drug industry's own risks and 377 related risks, involving 164 legal proceedings In addition, xiulaigui, the actual controller of the amended pharmaceutical industry, was also exposed to bribe officials in 2017 Xiulaigui has twice given a total of 250000 shares to Chu Laifu, a local official, to bribe, according to the official website The invisible "revenue fog" is calculated by revenue, and the revised pharmaceutical industry should be the top three pharmaceutical enterprises in China Is it difficult for pharmaceutical companies of this scale to go public? In fact, it's hard to understand how to fix the revenue of the pharmaceutical industry The amended pharmaceutical industry issued a bond of 300 million yuan in July 2014, and therefore disclosed the annual report of 2010-2014 According to the annual report, the revised pharmaceutical industry's revenue in 2010-2014 was 1.759 billion yuan, 1.989 billion yuan, 1.877 billion yuan, 2.722 billion yuan and 3.595 billion yuan respectively The financial data of the first quarter of 2015 shows that the revenue is 694 million yuan The following public data shows that in 2015, the revised pharmaceutical industry achieved revenue of 57.5 billion yuan In one year, the revised pharmaceutical industry's revenue has soared a hundred times In the last three quarters of 2015, there was no public information that the revised pharmaceutical industry had launched a new revolutionary product, which brought huge sales revenue, nor that the revised pharmaceutical industry had entered a new emerging industry with a sudden increase of 50 billion revenue It's hard to understand how to fix the 100 fold growth of the pharmaceutical industry If you want to IPO, you may need to explain the above situation to CSRC and investors The core competitiveness is weak, and the net profit growth is almost stagnant According to the existing public data, the pharmaceutical industry was revised to achieve sales revenue of 57.5 billion yuan in 2015, a year-on-year growth of 16%; in 2016, the sales revenue was about 63.6 billion yuan, a growth rate of 8.16%; in 2017, the sales revenue was 63.8 billion yuan, a growth rate of only 0.31% According to the existing performance data, the net profit growth of the modified pharmaceutical industry is almost stagnant Over the counter Chinese patent medicines are the main products in the pharmaceutical industry On the one hand, with the continuous increase of the national supervision of Chinese patent medicine products, the varieties of Chinese patent medicine will usher in a large-scale reshuffle On the other hand, the technical threshold of Chinese patent medicine is relatively low, and it is easy for competitors to squeeze the market space Currently, the most successful product in Revisioning the pharmaceutical industry is starshu But after more than ten years of development, Starwood has been close to its life cycle, and competing products such as Bayer Darcy and sunflower Weikangling are constantly emerging, all of which are seizing market share At present, the revised pharmaceutical industry has more than 100000 employees, but 80000 of them are sales personnel There are more than 60 billion yuan of annual revenue, but the annual scientific research expenditure is only about 1 billion yuan Facing the situation that the pharmaceutical industry pays more and more attention to innovation and R & D, it is insufficient to amend the market competitiveness of the pharmaceutical industry Editor in charge: penicillin is the content reprinted by yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.